Initially, HCV patients with glomerulopathies, in particular membrano- proliferative glomerulonephritis (MPGN), were treated with interferon (IFN) or peg-interferon (PEG-IFN) associated with ribavarin (RBV), but this therapy induced serious side effects and low sustained virologic response (SVR), often less than 50%3,4. The gene discussed is IFNA1; the disease is lipoprotein glomerulopathy.